Technical Coding Alignment for Prior Auth Processing of Select MIDs
Summary
Effective September 1, 2026, Highmark is aligning technical coding configurations for prior authorization processing of 20 select medical injectable drugs (MIDs), including new denosumab biosimilars and oncology/specialty drugs. This ensures consistency with previously published prior authorization requirements. While widespread impact is not anticipated, variations may occur based on individual benefit plans and eligibility.
Get alerts when payers change rules like this one
We check Highmark and other payers every day and email you when a change matches your specialty and state.